argenx SE
Develops first-in-class antibody therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
argenx SE is a global immunology company focused on developing and commercializing therapies for severe autoimmune diseases. The company leverages its proprietary antibody engineering platforms and a collaborative "antibody innovation ecosystem" to translate immunology breakthroughs into first-in-class medicines. Its primary commercial product is efgartigimod, marketed as VYVGART and VYVGART Hytrulo, for the treatment of conditions including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's pipeline includes additional antibody-based candidates targeting various autoimmune disease pathways.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-31 08:20 |
Earnings Release
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Bus…
|
English | 164.9 KB | ||
| 2025-07-31 07:31 |
Interim / Quarterly Report
argenx SE, Halfjaarlijkse financiële verslaggeving
|
English | 1.0 MB | ||
| 2025-07-24 08:15 |
Report Publication Announcement
argenx to Report Half Year 2025 Financial Results and Second Quarter Business U…
|
English | 169.3 KB | ||
| 2025-06-30 07:51 |
Legal Proceedings Report
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndr…
|
English | 50.6 KB | ||
| 2025-06-23 07:37 |
Regulatory Filings
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection…
|
English | 57.6 KB | ||
| 2025-06-11 08:15 |
Regulatory Filings
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase…
|
English | 154.7 KB | ||
| 2025-03-20 07:09 |
Annual Report (ESEF)
argenx SE, Jaarlijkse financiële verslaggeving
|
English | 33.5 MB | ||
| 2025-03-07 07:41 |
Environmental & Social Information
argenx Highlights FcRn Leadership with Long-term Data and Transformational Pati…
|
English | 180.7 KB | ||
| 2025-01-06 07:42 |
Regulatory Filings
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
|
English | 21.5 KB | ||
| 2024-12-27 08:43 |
Regulatory Filings
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc)…
|
English | 63.3 KB | ||
| 2024-11-26 07:38 |
Report Publication Announcement
argenx to Present at Upcoming Investor Conferences
|
English | 26.2 KB | ||
| 2024-11-11 13:45 |
Regulatory Filings
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammator…
|
English | 59.1 KB | ||
| 2024-11-05 07:35 |
Regulatory Filings
argenx to Participate at Upcoming Investor Conferences
|
English | 25.1 KB | ||
| 2024-10-31 07:40 |
Earnings Release
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
|
English | 154.5 KB | ||
| 2024-10-24 07:40 |
Regulatory Filings
argenx to Report Third Quarter 2024 Financial Results and Business Update on Oc…
|
English | 22.7 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
